Figure 5.

Mutations on the SARS-CoV-2 S in VOCs and resistance profile of clinical mAbs

(A) Ancestry tree of SARS-CoV-2 VOCs/VOIs.

(B) Schematic of SARS-CoV-2 S and the mutation landscape in each VOC/VOI. Del, deletion; ins, insertion.

(C) Neutralization of a selection of VOCs/VOIs by clinical-stage mAbs as reported previously (Baum et al., 2020b; Chen et al., 2021b, 2021c; Copin et al., 2021; Dejnirattisai et al., 2021; Dong et al., 2021; FDA (US Food and Drug Administration), 2020a, 2020b; Hoffmann et al., 2021; Liu et al., 2021b; McCallum et al., 2021a; Ryu et al., 2021; Starr et al., 2021b, 2021c; Thomson et al., 2021; Wang et al., 2021a, 2021b). Prediction of neutralization coverage is based on the presence of mutations in the available epitope of each mAb. mAbs developed clinically as cocktails are grouped.